SupportLoginSign Up
Featured FeedJournalsCollectionsKeywordsSaved Papers
Add like
Add dislike
Add to saved papers

Real-world Evaluation of Imipenem/cilastatin/relebactam across US Medical Centers.

Ryan K Shields, Emre Yucel, Vladimir Turzhitsky, Sanjay Merchant, Jae S Min, Alexandre H Watanabe
Journal of Global Antimicrobial Resistance 2024 April 7
We assessed 160 patients who received imipenem/cilastatin/relebactam for ≥2 days. At treatment initiation, median Charlson Comorbidity Index was 5, 45% were in the intensive care unit, and 19% required vasopressor support. The in-hospital mortality rate was 24%. These data advance our understanding of real-world indications and outcomes of imipenem/cilastatin/relebactam use.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.
Show additional links to paperHide additional links to paper
PubMed

Add to Saved Papers

Get 1-tap access

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Do Not Sell My Personal InformationManage Cookie Preferences

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app